Other Non-Current Liabilities
Alnylam Pharmaceuticals Other Non-Current Liabilities increased by 0.2% to $7.61M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 29.6%, from $5.87M to $7.61M. Over 5 years (FY 2020 to FY 2025), Other Non-Current Liabilities shows a downward trend with a -27.5% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
Significant changes may reflect shifts in lease accounting, changes in employee benefit plans, or the emergence of long-term legal risks.
Detailed definition
A catch-all category for long-term obligations that do not fall into major classifications like debt or deferred taxes....
Peer comparison
Varies significantly by industry; companies with large physical retail footprints often show higher values here due to long-term leases.
other_non_current_liabilitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $71.63M | $76.45M | $98.96M | $120.83M | $157.30M | $183.00M | $212.58M | $224.05M | $257.05M | $280.73M | $308.44M | $319.99M | $350.43M | $357.48M | $4.97M | $5.87M | $10.93M | $9.77M | $7.59M | $7.61M |
| QoQ Change | — | +6.7% | +29.4% | +22.1% | +30.2% | +16.3% | +16.2% | +5.4% | +14.7% | +9.2% | +9.9% | +3.7% | +9.5% | +2.0% | -98.6% | +18.2% | +86.2% | -10.6% | -22.3% | +0.2% |
| YoY Change | — | — | — | — | +119.6% | +139.4% | +114.8% | +85.4% | +63.4% | +53.4% | +45.1% | +42.8% | +36.3% | +27.3% | -98.4% | -98.2% | -96.9% | -97.3% | +52.8% | +29.6% |
Other Non-Current Liabilities at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's other non-current liabilities?
- Alnylam Pharmaceuticals (ALNY) reported other non-current liabilities of $7.61M in Q1 2026.
- How has Alnylam Pharmaceuticals's other non-current liabilities changed year-over-year?
- Alnylam Pharmaceuticals's other non-current liabilities increased by 29.6% year-over-year, from $5.87M to $7.61M.
- What is the long-term trend for Alnylam Pharmaceuticals's other non-current liabilities?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's other non-current liabilities has grown at a -27.5% compound annual growth rate (CAGR), from $37.91M to $7.59M.
- What does other non-current liabilities mean?
- Miscellaneous long-term debts and obligations that aren't due for at least a year.